Mylan NV (NASDAQ:MYL)

35.64
Delayed Data
As of 4:00pm ET
 -0.28 / -0.78%
Today’s Change
29.39
Today|||52-Week Range
47.82
-15.76%
Year-to-Date
AbbVie Authorizes U.S. Sale of Humira Biosimilar
Jul 18 / GuruFocus News - Paid Partner Content
Drug Pricing in Focus Again as Trump Tweet Slams Pfizer
Jul 10 / Zacks.com - Paid Partner Content
AbbVie Settles With Mylan to Delay Humira Biosimilar in U.S.
Jul 18 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close35.92
Today’s open35.81
Day’s range35.21 - 35.92
Volume3,065,686
Average volume (3 months)4,234,878
Market cap$18.5B
Data as of 4:00pm ET, 07/19/2018

Growth & Valuation

Earnings growth (last year)+41.30%
Earnings growth (this year)+15.92%
Earnings growth (next 5 years)+11.00%
Revenue growth (last year)+7.06%
P/E ratio26.4
Price/Sales1.91
Price/Book1.41

Competitors

 Today’s
change
Today’s
% change
BMRNBiomarin Pharmaceuti...+0.18+0.18%
PRGOPerrigo Company PLC-0.59-0.77%
JAZZJazz Pharmaceuticals...+1.06+0.60%
ALNYAlnylam Pharmaceutic...+0.89+0.84%
Data as of 4:00pm ET, 07/19/2018

Financials

Next reporting dateAugust 9, 2018
EPS forecast (this quarter)$1.23
Annual revenue (last year)$11.9B
Annual profit (last year)$696.0M
Net profit margin5.85%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Generic
Chief Executive Officer &
Executive Director
Heather M. Bresch
President &
Executive Director
Rajiv Malik
Corporate headquarters
Hatfield, Hertfordshire

Forecasts